Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, has announced upcoming presentations at two major healthcare investor conferences. CEO Wes Kaupinen will present at the Cantor Global Healthcare Conference on September 4, 2025, at 2:45 PM ET and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 10:30 AM ET.

The presentations will be accessible via live webcast on Palvella's website, with replays available for approximately 90 days afterward.

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:

Cantor Global Healthcare Conference
Thursday, September 4, 2025, at 2:45pm ET

H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025, at 10:30am ET

A live webcast of both presentations will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com

FAQ

When is Palvella Therapeutics (PVLA) presenting at the Cantor Global Healthcare Conference 2025?

Palvella's CEO will present at the Cantor Global Healthcare Conference on September 4, 2025, at 2:45 PM ET.

When is PVLA's presentation at the H.C. Wainwright Conference 2025?

The presentation at the H.C. Wainwright Global Investment Conference is scheduled for September 8, 2025, at 10:30 AM ET.

How can investors access Palvella Therapeutics' conference presentations?

Investors can access the live webcasts through the Events and Presentations section of Palvella's website at www.palvellatx.com. Archived replays will be available for 90 days after the presentations.

What is Palvella Therapeutics' (PVLA) main business focus?

Palvella is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious, rare genetic skin diseases that currently have no FDA-approved treatments.